Susquehanna International Group, LLP Neoleukin Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 11, 2023	BUY	$0.68 - $0.91 $9,656 - $12,922	14,200 New	14,200 $11,000
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.25 $28,520 - $69,750	-31,000 Reduced 35.07%	57,400 $59,000
Q1 2022 May 16, 2022	SELL	$1.72 - $5.23 $9,116 - $27,719	-5,300 Reduced 5.66%	88,400 $166,000
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.75 $268,770 - $447,950	57,800 Added 161.0%	93,700 $452,000
Q3 2021 Nov 15, 2021	BUY	$6.05 - $9.66 $15,730 - $25,116	2,600 Added 7.81%	35,900 $260,000
Q2 2021 Aug 11, 2021	SELL	$9.23 - $13.12 $46,150 - $65,600	-5,000 Reduced 13.05%	33,300 $307,000
Q1 2021 May 17, 2021	SELL	$11.26 - $15.78 $67,560 - $94,680	-6,000 Reduced 13.54%	38,300 $471,000
Q4 2020 Feb 16, 2021	BUY	$10.17 - $14.56 $325,440 - $465,920	32,000 Added 260.16%	44,300 $625,000
Q3 2020 Nov 16, 2020	SELL	$9.68 - $17.01 $154,880 - $272,160	-16,000 Reduced 56.54%	12,300 $148,000
Q1 2020 May 15, 2020	SELL	$6.12 - $13.64 $73,440 - $163,680	-12,000 Reduced 29.78%	28,300 $322,000
Q4 2019 Feb 14, 2020	BUY	$2.65 - $12.72 $106,795 - $512,616	40,300 New	40,300 $496,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.